

Administrative Report

Clinical Practice Guidelines for Management of Sarcoma
– Series 1



13th April 2022

Scope of the administrative report

This administrative report refers to the development of Clinical Practice Guidelines for Management of Sarcoma (Series 1).

Table of Contents

Preamble	3
Responsible Organisation	3
Funding	3
Multidisciplinary working party	3
Guidelines working party membership	4
Consumer Involvement	4
Declaration of conflict of interest	5
Funding	5
Meetings	5
Training for working party members	6
Consensus-based recommendations	6
Public consultation	7
Endorsement	8

Preamble

As the leading research organisation in sarcoma in Australia and New Zealand, the Australia and New Zealand Sarcoma Association (ANZSA) is dedicated to improving the outcome for patients with sarcoma through awareness, education, and research. ANZSA fosters effective collaborations across medical and psychosocial multidisciplinary teams (MDT), comprising specialist health professionals (including pathologists, radiologists, surgeons, radiation oncologists, medical oncologists, paediatric oncologists, and allied health) working together to identify the best management and care of patients with sarcoma and related tumours. Pivotal to this goal is the development and dissemination of clinical practice guidelines based on systematic review to evaluate evidence for best management of adult and paediatric patients with sarcoma. The previous Australian clinical practice guidelines for the management of adult onset sarcoma were published in 2013. This current guidelines development process was commenced at the end of 2020 with full support from the board and the scientific advisory committee of ANZSA. The working party uses evidence-based methodologies to develop guideline recommendations in accordance with the National Health and Medical Research Council (NHMRC) standard. (<https://www.nhmrc.gov.au/guidelinesforguidelines>).

Responsible Organisation

ANZSA is responsible for developing and dissemination of the guidelines. ANZSA is a not for profit organisation and the operations are funded by Cancer Australia grant. Its vision is to improve early diagnosis, treatment options, outcomes, and quality of life of patients with sarcomas and related tumours through outstanding national and international, basic, translational, clinical, and supportive care research and clinical trials.

Funding

The guidelines development is solely funded by ANZSA to cover guideline development training (GRADE training and The International Guideline Credentialing and Certification (INGUIDE) Program), publication, and dissemination. There is no commercial support.

Apart from the project manager, members of the working party volunteer their time to participate in the guideline development.

Multidisciplinary working party

The management of sarcoma is complex and involves the input of a multidisciplinary team to achieve the optimal outcome. Therefore, it was decided that the working party should include experts from multidisciplinary medical speciality such as radiation oncology, medical oncology, orthopaedic surgery, surgical oncology, paediatric/adolescent young adult oncology, pathology as well as end-users such as a general oncology, general practice, psychology, and consumer. A clinical librarian with expertise in systematic review has assisted with literature search and the systematic management software system Covidence.

A call for expression of interest with the terms of reference was sent to members of scientific advisory committee and the consumer advisory party of ANZSA on the 14th August 2020. The guideline chair and ANZSA CEO reviewed the applications to ensure the working party consists of multidisciplinary group with variation in areas of expertise in sarcoma management, geographic region, gender, and practice setting. To foster the next generation of medical specialist, advanced trainees in radiation oncology, medical oncology, surgical oncology, and orthopaedic surgery were invited to participate in the systematic review and guidelines development.

At the first guideline working party meeting on 7th December 2020, the members discussed and voted on the theme of three broad topics (specialised sarcoma care, retroperitoneal sarcoma, paediatric/AYA sarcoma). The working party was then divided into three smaller working groups each with a topic lead. Each topic working group focused their attention on the specific topics and the agreed research questions. The smaller topic working groups worked on the systematic reviews and the initial draft recommendations before presenting to the whole working group for further feedback and discussion. Despite the relatively large size of the working party, all members worked efficiently together in their smaller topic working groups and made valuable contributions in the areas of their expertise.

Guidelines working party membership

Please see Appendix 1. Working Party Members for the full list of the Sarcoma Guidelines Working Party Members.

Consumer Involvement

A call for expression of interest with the terms of reference was sent to all consumer members of the ANZSA Consumer Advisory Party (CAP) on the 14th August 2020. The consumers are volunteers with the purpose to assist in research and academic endeavours for ANZSA. The CAP has a Terms of Reference that serves as a policy for engagement and support of consumer members. Two consumers accepted a role as working group members in the guideline working group.

Both consumers were involved in the initial guideline development process and participated in initial discussions at end of 2020 to determine the focus of the guideline questions. They were also invited to take part any educational courses for example GRADE training and Covidence training. They were included in all communications with the opportunity to contribute at any stage. Furthermore, they were offered support in terms of further explanation and discussion of the more technical aspects of the guideline development process as needed. Both were involved in the final evaluation of the guideline recommendations and the plain English summary.

A third consumer (independent of the guideline development process) will also take part as an independent reviewer of the draft guidelines.

During the public consultation period, the key sarcoma consumer advocacy groups are individually invited to review and comment.

Declaration of conflict of interest

To ensure a guideline's recommendations are objective and unbiased all members are asked to declare their interests. The term of reference for guidelines working party clearly stated the need to declare any potential conflict of interest at the beginning of the membership and during the course of the membership should one arise. A declaration form is completed by each member at the beginning of the membership.

Throughout the guideline development, members are reminded of their obligation to consider any interest that may have arisen since the last meeting or with any agenda items. No potential competing interests have been identified that required a formal management plan. Please see Appendix 2 for the Conflict of Interest Register.

Funding

The ANZSA board approved a budget of \$27,000 for guideline development in 2020 to include training, software and project officer's salary. ANZSA has not sought any commercial funding for this guideline development.

Meetings

Each meeting is chaired by the chair of the guidelines working party and relevant members are invited to join. The agenda and relevant reading materials are provided at least one week prior to each meeting. The minutes of the meeting and follow up reading materials are provided to the working party within 2 weeks. The initial plan was to hold day-long face to face meetings to appraise the systematic review, and vote on the final evidence summary and recommendations. Due to Covid 19 pandemic, these meetings were convened as shorter virtual meetings (meeting dates to discuss draft guideline recommendations are listed below):

9th February 2022 – Topic 1 group meeting
1st March 2022 – Topic 3 group meeting
7th March 2022– Topic 1 group meeting

In addition, the chair and the project officer meet virtually every two weeks to manage the progress of the guidelines development. The chair and the project manager have also met with more junior members of the working party individually to provide guidance and support.

Training for working party members

A series of educational courses were provided to the working party member to support their understanding of the systematic review and guidelines development.

GRADE Workshop, presented by Associate Prof Zachary Munn, Director JBI Adelaide GRADE Centre, Joanna Briggs Institute

Date: 24th November 2020

Attendees: Angela Hong, Denise Caruso, Jasmine Mar, Lisa Orme, Fiona Maclean, Joshua McDonough, Marianne Phillips, Smaro Lazarakis, Jeremy Lewin, Natacha Omer, Susie Bae, Elizabeth Connolly, Vivek Bhadri, Peter Lee

**Workshop recording and materials were made available to all members of the working party after the workshop*

Covidence Training Webinar

Host: Covidence Community Manager Nancy Owens

Attendees: Angela Hong, Denise Caruso, Jasmine Mar, Peter Grimison, Fiona Maclean, Anna Lawless, Marianne Phillips, Smaro Lazarakis

**Workshop recording and materials were made available to all members of the working party after the webinar*

The International Guideline Credentialing and Certification (INGUIDE) Program by the Guidelines International Network and McMaster University

Date: Self-paced learning available from 21st October 2021 onwards

Attendees: Angela Hong, Jasmine Mar, Natacha Omer, Julie Cayrol

Consensus-based recommendations

In order for working party members to appraise the evidence for each question, each is provided with:

- access to Covidence systematic management system which has all publications included in the title/abstract screening, full text screening, the Prisma diagram, the pdf of all publications that meet the inclusion criteria and the data extraction
- an excel file with evidence table, which summarises the systematic review and critical appraisal of all studies that meet the inclusion criteria
- final quality assessment (NHMRC Evidence Hierarchy, Newcastle-Ottawa Quality Assessment Form for Cohort Studies, Cochrane Collaboration's tool for assessing risk of bias for randomised trial) for each publication that meet the inclusion criteria
- a draft guideline with evidence summary, recommendations and practice points at prior to topic working party meeting

During each meeting, the chair provides an overall view of the NHMRC guidelines for guidelines development, the NHMRC grades of recommendations and the NHMRC evidence statement criteria. Each topic lead then presents the summary of the systematic review

including areas of weak evidence, the evidence summary, recommendations, and practice points. All members are invited to contribute, debate and vote during the meeting. The draft guidelines are revised after the meeting based on the discussion and circulated to each member of the topic working party as well as the whole guidelines working party for review and final approval. Any dissenting views are freely discussed among members until a final decision can be reached based on the best evidence available. Each recommendation and practice point are reached by majority vote provided by the working party.

Independent review

The guidelines and recommendations are in the process of being assessed by at two reviewers (a surgical oncologist in NSW and a consumer from the WEHI Consumer Advisory Panel). The reviewers are independent of the guideline development process and will assess the guidelines using the AGREE II instrument. Both reviewers will complete a declaration of conflict of interest form. Comments provided by the independent reviewers will be presented for consideration by all members of the guidelines working party.

Public consultation

The draft of the guidelines with its technical and administrative reports are released for publication consultation for a minimum period of 30 days from 22nd March 2022 to the 22nd of April 2022. ANZSA will be soliciting comments from its members by direct email alert and listing the draft guidelines on its website.

During the public consultation period, the Director-General, Chief Executive or Secretary of each state, territory and Commonwealth health department are invited to comment. An invitation letter/email with a link to ANZSA website listing the draft guidelines will be sent immediately prior to public consultation.

The following professional and consumer organisations have been identified as key stakeholders that will be involved in, or affected by, the implementation of the clinical recommendations of the guideline. Each organisation is individually invited to provide comments and will consider any necessary revisions after the public consultation period.

- Royal Australia and New Zealand College of Radiologists, Faculty of Radiation Oncology (RANZCR)
- Medical Oncology Group of Australia (MOGA)
- Royal Australasian College of Surgeons (RACS)
- Australia Orthopaedic Association (AOA)
- Clinical Oncology Society of Australia (COSA)
- Australia and New Zealand Children Haematology Oncology Group (ANZCHOG)
- Royal Australian College of General Practitioners (RACGP)
- Sock it to Sarcoma (Consumer organisation)
- Rainbows for Kate (Consumer organisation)
- Rare Cancers Consumer Group (Consumer organisation)
- Kicking Goals for Xav (Consumer organisation)

All comments will be considered by the chair and members of the topic working party. Changes will be made to the draft guidelines when it is considered as appropriate. A public consultation summary table listing each comment resulted in a change to the guidelines, or that the comment was considered but did not result in a change, and the reasons why it did not will be kept. A de-identified version of the public consultation summary and the changes made to the guideline as a result will be published with the final guidelines.

Endorsement

We will be seeking endorsement from professional organisations in Australia and New Zealand.

Appendix 1. Working Party Members

Title	First Name	Last Name	Profession	Representation	Role in Guideline Development Process
Prof	Angela	Hong	Radiation Oncologist	Royal Prince Alfred Hospital/Chris O'Brien Lifehouse, NSW	Chair and Topic 1 Lead
Dr	Susie	Bae	Medical Oncologist	Peter MacCallum Cancer Centre, VIC	Working Group Member
Dr	Vivek	Bhadri	AYA Medical Oncologist	Royal Prince Alfred Hospital/Chris O'Brien Lifehouse, NSW	Working Group Member
Prof	Richard	Carey Smith	Orthopaedic Surgeon	Sir Charles Gairdner Hospital, WA	Working Group Member
Dr	Denise	Caruso	Chief Executive Officer	Australia and New Zealand Sarcoma Association Limited	Working Group Member
Dr	Julie	Cayrol	Paediatric and AYA Medical Oncologist	Royal Children's Hospital, VIC	Working Group Member
Prof	Peter	Choong	Orthopaedic Surgeon	St Vincent's Hospital Melbourne, VIC	Working Group Member
Dr	David	Cocker	Surgical Oncology Fellow	Royal Prince Alfred Hospital, NSW	Working Group Member
Dr	Elizabeth	Connolly	Medical Oncologist/PhD Candidate	Chris O'Brien Lifehouse, NSW	Working Group Member
A/Prof	Jayesh	Desai	Medical Oncologist	Peter MacCallum Cancer Centre, VIC	Working Group Member
Ms	Natalia	Dewiyani	Consumer Representative	Consumer Representative, VIC	Working Group Member
A/Prof	Peter	Grimison	Medical Oncologist	Royal Prince Alfred Hospital/Chris O'Brien Lifehouse, NSW	Working Group Member
A/Prof	David	Gyorki	Surgical Oncologist	Peter MacCallum Cancer Centre, VIC	Topic 2 Lead & Working Group Member
Dr	Anna	Lawless	Radiation Oncology advanced trainee	Chris O'Brien Lifehouse, NSW	Working Group Member
Ms	Smaro	Lazarakis	Clinical and Research Librarian	Peter MacCallum Cancer Centre, VIC	Clinical and Research Librarian
Dr	Peter	Lee	Surgical Oncologist	Royal Prince Alfred Hospital, NSW	Working Group Member
Dr	Jeremy	Lewin	AYA Medical Oncologist	Peter MacCallum Cancer Centre, VIC	Working Group Member
Dr	Tracy	Lim	Radiation Oncology advanced trainee	Chris O'Brien Lifehouse, NSW	Working Group Member
Dr	Helen	Lo	Radiation Oncologist	Port Macquarie Based Hospital	Working Group Member
A/Prof	Fiona	Maclean	Pathologist	Douglass Hanly Moir Pathology, NSW	Working Group Member
Ms	Jasmine	Mar	Research Coordinator	Australia and New Zealand Sarcoma Association Limited (ANZSA)	Project Officer
Dr	Joshua	McDonough	Scientist	The University of Adelaide, SA	Working Group Member
Dr	Wayne	Nichols	Paediatric and AYA Medical Oncologist	Queensland Children's Hospital, QLD	Working Group Member
Dr	Natacha	Omer	Paediatric Medical Oncologist	Queensland Children's Hospital, QLD	Topic 3 Lead & Working Group Member
Dr	Lisa	Orme	Paediatric and AYA Medical Oncologist	The Royal Children's Hospital Melbourne/Peter MacCallum Cancer Centre, VIC	Working Group Member
Dr	Charlotte	Payne	General Practitioner	General Practitioner, NSW	Working Group Member
Dr	Ganapathy	Perianayagam	Orthopaedic Tumour Fellow	Royal Prince Alfred Hospital, NSW	Working Group Member
A/Prof	Marianne	Phillips	Paediatric and Adolescent Medical Oncologist/Palliative Care Physician	Perth Children's Hospital, WA	Working Group Member
A/Prof	David	Pryor	Radiation Oncologist	Princess Alexandra Hospital, QLD	Working Group Member
Ms	Ashika	Ramamurthy	Medical Student	University of Sydney, NSW	Working Group Member
Dr	Richard	Smith	Surgical Oncologist	Royal Adelaide Hospital, SA	Working Group Member
A/Prof	Peter	Steadman	Orthopaedic Surgeon	Princess Alexandra Hospital, QLD	Working Group Member
Dr	Abay	Sundaram	Orthopaedic Fellow	Sir Charles Gairdner Hospital, WA	Working Group Member
Dr	Stephen	Thompson	Radiation Oncologist	Prince of Wales Hospital, NSW	Working Group Member
Ms	Julijana	Todorovic	Consumer Representative	Consumer Representative, VIC	Working Group Member
Dr	Cristina	Vargas	Pathologist	Douglass Hanly Moir Pathology, NSW	Working Group Member
Ms	Jennifer	Vu	Medical Student	University of Sydney, NSW	Working Group Member
Dr	Mark	Winstanley	Paediatric Medical Oncologist	Starship Hospital, New Zealand	Working Group Member
Dr	Mei	Zhang	Research Assistant	The University of Sydney, NSW	Working Group Member
Dr	Betty	Zhang	Medical Oncology Sarcoma Fellow	Chris O'Brien Lifehouse, NSW	Working Group Member
Dr	Deborah	Zhou	Medical Oncology Sarcoma Fellow	Chris O'Brien Lifehouse, NSW	Working Group Member

Appendix 2. Conflict of Interest Register

Title	First Name	Last Name	Current employment and previous employment with continued financial interest	Appointments e.g. trusteeships, Boards, committees & tribunals	Membership of professional bodies, specialist societies, etc	Direct or indirect payment of a financial or other benefits from industry – provide specific details of payments or benefits in the past 12 months (incl date, company and reason for payment)	Other conflicts
Dr	Susie	Bae	Eastern Health, Peter MacCallum Cancer Centre, ANZSA	Nil	ASCO, ESMO, CTOS	Nil	Nil
Dr	Vivek	Bhadri	Chris O'Brien Lifehouse	Nil	ANZSA	Nil	Nil
Prof	Richard	Carey Smith	Perth Orthopaedics + Sports Medical Centre, Perth Bone Bank (PlusLife), Sir Charles Gardner Hospital, Perth Children's Hospital	Board member of ANZSA, AOA, WA AOA, Sock it to Sarcoma	AOA, RACS, BOA, RCS (Eag), ANZSA	Consulting - Zimmer Biomet, Lifehealthcare, DePuy Synthes, Ossis	
Dr	Denise	Caruso	Peter MacCallum Cancer Centre & CEO ANZSA	Nil	COSA, CTOS, ACTA, SARC	Nil	Nil
Dr	Julie	Cayrol	Monash Children's Hospital	Nil	SIOP (International society for paediatric oncology), COG (Children's Oncology Group), ANZSA, FRACP	Nil	Nil
Prof	Peter	Choong	University of Melbourne, St. Vincent's Hospital Melbourne	Head of Department of Surgery Family Trust, Board Committee of AOA Research, Emeritus Board member MSK Australia, Multiple university committees	AOA, ANZSA, ISOLS, APMSTS, AAOS, AAHMS	Consultancies with Stryker, Johnson and Johnson, Medacta	Nil
Dr	David	Coker	Melanoma Institute Australia (MIA) Royal Prince Alfred Hospital and Chris O'Brien Lifehouse	Clinical Senior Lecturer, The University of Sydney	Fellow of the Royal Australasian College of Surgeons Member of General Surgeons Australia Member of Australia and New Zealand Sarcoma Association	Nil	Nil
Dr	Elizabeth	Connolly	Chris O'Brien Lifehouse	ANZSA ambulatory chemotherapy working group, RACP AMDAC- adult medicine division assessment committee	CTOS, ANZSA, MOGA	Nil	Nil
Dr	Jayesh	Desai	Peter MacCallum Cancer Centre	Chair, Board of Directors- Cancer Trials Australia, Director, ANZSA	ANZSA, ASCO, ESMO, SARC	Consulting: Pierre-Fabre, Novartis, Amgen, Eisai, Roche/Genentech, Beigene, Checkpoint therapeutics Institutional Research Grants: Novartis, Roche/Genentech, BMS, Bionomics, GSK, Beigene	Nil

Ms	Natalia	Dewiyani	Consumer Representative				
A/Prof	Peter	Grimison	Chis O'Brien Lifehouse, Federal Department of Health - member, Pharmaceutical Benefits Advisory Committee	ANZSA - Scientific Advisory Committee	Australia New Zealand Sarcoma Association, Royal Australasian College of Physicians, Medical Oncology Group of Australia	Direct: nil Indirect: 1. Site principal investigator on trials conducted by Gilead (GS-2475); Tigermed (INCSHR01210); Pfizer (Avelumab); Merck (Pembrolizumab); Boston Biomedical (BBI-608); Medimmune (MEDI4736/Durvalumab & Tremelimumab); Halozyme (PEGPH20); Aslan Pharmaceuticals (Varlitinib); Janssen (Erdafitinib); Prime Therapeutics (Bemarituzumab); Epizyme (Tazemetostat); Plexikon (PLX3397, ie. Pexidartinib); Five Prime Therapeutics (FPA144, ie. bemarituzumab); Novartis (Panobinostat); QED (Infigratinib); and investigator-led trials with drug supply of Trastuzumab emtansine (T-DM1) by Roche, and of Durvalumab & Tremelimumab by Astra Zeneca 2. Member of trial management committee of investigator-led trial with drug supply of Pembrolizumab by Merck. 3. Study chair for trial with drug supply by Tilray (TN TC11M) 4. Participation in expanded access programs conducted by Merck (Pembrolizumab), Bristol Myers Squibb (Nivolumab), Astra Zeneca (Durvalumab), and Specialised Therapeutics Australia (Trabectedin)	Nil
Dr	David	Gyorki	Peter MacCallum Cancer Centre, Austin Health, Victorian Comprehensive Cancer Centre – Research & Education Lead, Skin & Melanoma Peter MacCallum Cancer Centre	Surgical Oncology Committee, Royal Australasian College of Surgeons, Australian Melanoma Guidelines Working Group, NHMRC, International Retroperitoneal Sarcoma Registry – Governance Committee	Society of Surgical Oncology, Connective Tissue Oncology Society, American Society of Clinical Oncology	Advisory Board – Qbiotics, Amgen, Bayer	Nil
Prof	Angela	Hong	Chris O'Brien Lifehouse (Staff Specialist), RPA (HMO), Genesis Cancer Care (VMO)	University of Sydney (clinical title), Faculty member of Melanoma Institute Australia,	Fellow of Royal Australia and New Zealand College of Radiologists, COSA member, Connective Tissue Oncology Society member	The Limbic: Speaker fee, Q-biotics Paid member of the data safety monitoring board, Uptodate: authorship fee, Bayer: advisory board fee, Oncobeta: advisory board fee	Nil

Dr	Anna	Lawless	Radiation Oncology Registrar at Chris O'Brien Lifehouse and Royal Prince Alfred Hospital, Sydney Local Health District (with rotations to RNSH and Lismore Hospitals in 2021)	Honorary lecturer at Sydney Medical School	Trainee member of Royal Australian and New Zealand College of Radiologists (RANZCR), Thoracic Oncology Group of Australasia (TOGA) and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)	Nil	Nil
Ms	Smaro	Lazarakis	Clinical Librarian, Royal Melbourne Hospital	Nil	Nil	Nil	Nil
Dr	Peter	Lee	Royal Prince Alfred Hospital		RACS		
Dr	Jeremy	Lewin	Peter MacCallum Cancer Centre	Nil	ANZSA, ANZUP	Nil	Nil
Dr	Tracy	Lim	NSW radiation oncology advanced trainee				
Dr	Helen	Lo	Port Macquarie Hospital	Nil	Nil	Nil	Nil
A/Prof	Fiona	Maclean	Douglas Hanly Moir Pathology	President Elect of International Academy of pathology (IAP) Australasian Div, Clinical Associate Professor Macquarie University, Committee member of Global Society of Rare GU tumours	IAP, ANZSA, Royal College of Pathologists Australasia, ANZVP member, Australian Institute of Company Directors	AbbVie March 2020 Speaker for genitourinary meeting	Nil
Ms	Jasmine	Mar	Peter MacCallum Cancer Centre - ANZSA	Nil	ANZSA	Nil	Nil
Dr	Joshua	McDonough	The University of Adelaide	Nil	Nil	Nil	Nil
Dr	Wayne	Nicholls	Queensland Children's Hospital	ANZSA & ANZCHOG - Scientific Advisory Committee (SAC)	SIOP, ANZCHOG, COGNO, COG, SNO, ANZSA	Nil	Nil
Dr	Natacha	Omer	Queensland Children's Hospital	Nil	COG, SIOP, ANZCHOG, ASCO, ANZSA, CTOS	Nil	Nil
Dr	Lisa	Orme	Royal Children's Hospital, Peter MacCallum Cancer Centre	ANZSA - Scientific Advisory Committee	ANZSA, RACP, CTOS, COG	Nil	Nil
Dr	Charlotte	Payne	Cardiff Medical Centre and Skin Cancer Clinic	Nil	RACGP	Nil	Nil
Dr	Ganapathy (Ganaps)	Perianayagam	Tumour and Arthroplasty Fellow, Royal Prince Alfred Hospital	Nil	Australian Medical Council, Fellow of Royal College of Surgeons, Edinburgh	Nil	Nil
A/Prof	Marianne	Phillips	Perth Children's Hospital	ANZSA Board, Children's Oncology Group Principal Investigator, ICPCN Board, PaPCANZ Executive, ANZCHOG Solid Tumour Committee, Redkite Governor	COG, ANZCHOG, SIOP, CCLG, COSA, PCA, PaPCANZ, RCP, RCPCH	Nil	Nil
A/Prof	David	Pryor	Princess Alexandra Hospital	ANZSA Scientific Advisory Committee	ANZSA FRANZCR	24-2-2020 ROCHE Advisory Board	

Ms	Ashika	Ramamurthy					
Dr	Richard	Smith	Royal Adelaide Hospital				
A/Prof	Peter	Steadman	Medhealth Australia, Medilaw group Australia, Queensland Health Princess Alexandra and Queensland Children's Hospitals, Private practice "Steadman Orthopaedics", University of Queensland	Chairman Queensland Orthopaedic research trust institute, International society of Limb Salvage, International skeletal society	AOA, AMA, RACS, AAOS		Nil
Dr	Stephen	Thompson	Prince of Wales Hospital	NSW CI, RANZCR, GOROC, UNSW TCRN/SPHERE, ANZSA SAC	RANZCR, GITG, TROG, COSA, ANZSA, ALLG	Nil	Nil
Ms	Julijana	Todorovic	Consumer Representative				
Dr	Elissa	Tong	NSW Health - Royal North Shore Hospital	Nil	Trans Tasman Radiation Oncology Group member	Nil	Nil
Dr	Cristina	Vargas	Consultant in Histopathology - Douglass Hanly Moir Pathology, Newcastle Research Affiliate: Kolling Institute of Medical Research, the Faculty of Medicine and Health, The University of Sydney	Research Affiliate and member of the Research/Postgraduate teaching committee (USYD Specialty of Clinical Pathology).	The Royal College of Pathologists of Australasia United States and Canadian Academy of Pathology	Nil	Nil
Ms	Jennifer	Vu	Nil	Nil	Nil	Nil	Nil
Mr	Mark	Winstanley	Starship Children's Hospital, Auckland District Health Board	Nil	RACP, COG, ANZCHOG	Nil	Nil
Dr	Mei	Zhang	Nil	Nil	Nil	Nil	Nil
Dr	Deborah	Zhou	Medical Oncology Fellow (Sarcoma) at Chris O'Brien Lifehouse, Sydney	Nil	ANZSA , MOGA – Medical Oncology Group of Australia , ESMO – European Society of Medical Oncology, ASCO – American Society of Clinical Oncology, AGITG – Australasian Gastro-Intestinal Trials Group	Nil	Nil